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Molecular Basis of Phospholipase A2 Inhibition
by Petrosaspongiolide M
In memory of Guido Sodano
Fabrizio Dal Piaz,[b] Agostino Casapullo,[a] Antonio Randazzo,[c] Raffaele Riccio,[a]
Piero Pucci,[b] Gennaro Marino,[b] and Luigi Gomez-Paloma*[a]
Petrosaspongiolide M (PM) is an anti-inflammatory marine metab-
olite that displays a potent inhibitory activity toward group II and III
secretory phospholipase A2 (PLA2) enzymes. The details of the
mechanism, which leads to a covalent adduct between PLA2 and -
hydroxybutenolide-containing molecules such as PM, are still a
matter of debate. In this paper the covalent binding of PM to bee
venom PLA2 has been investigated by mass spectrometry and
molecular modeling. The mass increment observed for the PM±
PLA2 adduct is consistent with the formation of a Schiff base by
reaction of a PLA2 amino group with the hemiacetal function
(masked aldehyde) at the C-25 atom of the PM -hydroxybuteno-
lide ring. Proteolysis of the modified PLA2 by the endoprotease LysC
followed by HPLC MS analysis allowed us to establish that the PLA2
-amino terminal group of the Ile-1 residue was the only covalent
binding site for PM. The stoichiometry of the reaction between PM
and PLA2 was also monitored and results showed that even with
excess inhibitor, the prevalent product is a 1:1 (inhibitor :enzyme)
adduct, although a 2:1 adduct is present as a minor component.
The 2:1 adduct was also characterized, which showed that the
second site of reaction is located at the -amino group of the Lys-85
residue. Similar results in terms of the reaction profile, mass
increments, and location of the PLA2 binding site were obtained for
manoalide, a paradigm for irreversible PLA2 inhibitors, which
suggests that the present results may be considered of more
general interest within the field of anti-inflammatory sesterter-
penes that contain the -hydroxybutenolide pharmacophore.
Finally, a 3D model, constrained by the above experimental results,
was obtained by docking the inhibitor molecule into the PLA2
binding site through AFFINITY calculations. The model provides an
interesting insight into the PM±PLA2 inhibition process and may
prove useful in the design of new anti-inflammatory agents that
target PLA2 secretory enzymes.
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Introduction
Sesterterpenes of marine origin that contain the -hydroxybu-
tenolide moiety have been studied for their potent anti-
inflammatory activity since the discovery in 1980 of manoalide[1]
(MLD, 1, Scheme 1), which can be considered the reference
compound within this class of bioactive natural products. Since
then, many other related molecules have been isolated, such as
seco-manoalide,[2] luffariellolides,[3] luffariellins,[4] luffolide,[5] ca-
cospongionolides,[6] and recently petrosaspongiolides M-R,[7] all
of which are capable of irreversible inhibition of PLA2. Among
these compounds, petrosaspongiolide M (PM, 2) has been the
subject of detailed in vitro and in vivo pharmacological
investigation. PM shows an IC50 value of 0.6 M toward bee
venom PLA2 (MLD has an IC50 value of 7.5 M under the same
conditions),[7, 8] it is able to reduce the levels of prostaglandin E2,
tumor necrosis factor , and leucotriene B4 in a dose-dependent
fashion,[9] and it has been shown to modulate the expression of
inducible cyclooxygenase and nitric oxide synthetase by inter-
ference with the nuclear factor B.[10] Since PM shows no
significant side effects that act on gastric mucosa at 10 mgKg1
and is orally administrable, there is considerable interest in the
design of simplified analogues of this molecule as new potential
candidates for the treatment of acute and/or chronic inflamma-
tion.
A number of investigations on the molecular aspects of PLA2
inactivation by -hydroxybutenolide-containing molecules and
in particular by MLD (1) have been reported. These investiga-
tions included biomimetic studies on the reaction of MLD with
amino acids and peptides,[11] structure ± activity relationships,[12]
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evidence that human-synovial PLA2 was also irreversibly inacti-
vated by MLD,[13] and a tentative location of the MLD binding site
on bee venom PLA2 at the -amino group of the Lys-88
residue.[14] When the location of the binding site was performed
an incorrect sequence of PLA2 was available (notably, in the
correct sequence there is no Lys-88 residue, see Scheme 1).[15]
Studies on the reaction mechanism were also undertaken and
provided evidence for a nucleophilic attack by an amino group
(for example, an -amino group of a Lys residue) on the
hemiacetal function(s), or masked aldehydes, at the C-25 and
C-24 atoms of MLD, which results in the formation of imine(s)
termed Schiff bases.[16] Molecular modeling studies on the MLD±
PLA2 interaction that lead to the proposal of the Lys-94 residue
as the best candidate for the imine formation have also been
reported.[17] According to this model, the polar tail of MLD (1)
interacts with a cationic site that consists of the Arg-58 and Lys-
94 residues, whereas its hydrophobic core lies in a cleft defined
by two  sheets in the C-terminal region of the enzyme. Overall,
the wealth of research activity fostered by this family of natural
products has indicated that their chemical mechanism of action
is still a matter of debate. In this paper we report a detailed
structural study of the inhibition of bee venom PLA2 by PM (2)
and MLD (1).
Results and Discussion
Our study consisted of four main goals: a) determination of the
nature and stoichiometry of the covalent binding of PM to PLA2,
aimed at understanding the chemical inactivation mechanism;
b) location on the PLA2 protein of the PM covalent binding
site(s) ; c) extension of the study to the case of MLD; d) con-
struction of a suitable 3D structural model of the PM±PLA2
interaction by using our results as
input data. Accordingly, from an ex-
perimental point of view the work can
be divided into the following steps:
a) comparative mass spectrometry
analysis of the intact and covalently
modified PLA2 species; b) proteolytic
digestion of both the free and inhib-
itor-bound protein samples followed
by HPLC purification and mass spec-
trometry analysis of the fragments
that result ; c) molecular modeling of
the inhibitor ± PLA2 complex.
All the experiments were initially
applied to the study of PLA2 inhibition
by PM and, after careful adjustment of
the experimental conditions, a parallel
set of experiments was performed to
investigate the mode of action of MLD
and thus allow a comparison of the
data to be made and the proposed
model of PLA2 inactivation to be put
on a more firm and general ground.
Chemical mechanism of covalent inhibition of PLA2 by PM
Bee venom PLA2 was incubated with a 1 ±5 molar excess of PM
at 40 C for 5 min in an Na2B4O7 buffer solution (10 mM, pH 7.4).
The mixture was treated with excess NaBH4 in order to selectively
reduce the Schiff base (imine) conceivably formed during the
incubation. This step allowed us to overcome the inherent
instability of the Schiff bases during MS analysis. The NaBH4
reaction products were then fractionated by reversed-phase (RP)
HPLC (Figure 1) and identified by electrospray mass spectrom-
etry (ESMS). Four major species were detected in the chromato-
gram and identified. These species consisted of unreacted PLA2
with one or two oxidized Met (ox-Met) species (peaks 1 and 2,
respectively, Figure 1), a monomodified (peak 3) and a dimodi-
fied (peak 4) PLA2 species. The ESMS analysis of the inhibitor-
bound PLA2 samples showed mass values of 16594.71.6 Da
and 17039.11.5 Da, which corresponds to an increase com-
Figure 1. RP HPLC chromatogram of the separation of PM/PLA2 reaction
products. Ar(220 nm) is the relative absorbance at 220 nm. Mass spectrometry
analyses of each fraction are reported in Table 1.
Scheme 1. The amino acid sequence of bee venom phospholipase A2 (PLA2) and the chemical structures of
manoalide and petrosaspongiolide M.
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pared to unreacted PLA2 of 444 Da and 888 Da for the mono- and
dimodified PLA2 forms, respectively (molecular weight of intact
PLA216150.1 1.6 Da; Table 1). Hence, molecular mass differ-
ences detected between reacted and unreacted PLA2 species
were very informative with regard to the stoichiometry of the
modifications and revealed that the most relevant reaction
product in these conditions is a 1:1 covalent PM±PLA2 adduct,
which occurs along with a 2:1 complex minor product. MS data
were also used to address one of the most crucial points in the
study of the chemical mechanism that lies behind PLA2
inactivation by PM and related molecules, which allowed us to
propose a detailed reaction pathway fully consistent with all the
experimental evidence (see below). Such a proposal in turn
requires an accurate analysis of all the reactive centers of the
inhibitor molecule. Although several possibilities arise when a
nucleophilic attack by a PLA2 amino group at an electrophilic site
of the sesterterpene 2 is considered, some of these possibilities
(such as a Michael addition to the conjugate ester carbonyl in the
butenolide moiety) can be ruled out by taking into account
literature data.[16] This process leaves the formation of an imine
from a hemiacetal/aldehyde as the only mechanism in agree-
ment with all the experimental evidence collected so far.
Chemical evidence that (reversible) formation of an imine is
the key step in the inactivation pathway was obtained by
treatment of a sample of PLA2 preincubated with PM with a
hydroxylamine solution (1:10 molar ratio of protein to hydroxyl-
amine) for 5 minutes to yield the corresponding PM oxyme and
release the free (and active) form of PLA2. HPLC and ESMS
analysis of the reaction mixture that results showed the presence
of only the unmodified protein species, which supports imine
formation.[16] A parallel experiment was performed in which
hydroxylamine was added to the PM±PLA2 reaction product
after reduction with NaBH4. As expected, in this case LC ±MS
detected a mixture of mono- and dimodified PLA2 species, much
like that seen in the case of simple PM±PLA2 incubation.
However, a further complication stems from the presence in
the PM molecule (as well as other related inhibitors) of two
reactive sites, that is, C-25 and C-24 hemiacetal groups. Even if in
the specific case of PM the C-24 hemiacetal group is present as
an acetyl derivative and therefore much less sensitive to
nucleophilic attack, since PLA2 may work as a generic esterase
a reactivation of this functionality by a PLA2-catalyzed hydrolysis
of the acetate in a sort of a suicide mechanism remains a
possibility. The mass increment of 444 Da observed for the
monomodified PLA2 species (after NaBH4 reduction and hence
corresponding to a Mboundfree of 442 Da) allowed us to
discriminate between two reaction mechanisms that may be
postulated on the basis of the previous considerations
(Scheme 2). The expected mass increments (after NaBH4 reduc-
tion) for the two putative reaction pathways for PM±PLA2
inactivation are 444 Da for a single Schiff base formation at the
C-25 atom in the butenolide ring of PM and 386 Da for a
bidentate mode of binding, which requires the PLA2-catalyzed
deacetylation of PM at the C-24 atom followed by formation of
two imines at the C-24 (pyran ring) and C-25 (butenolide ring)
positions (Scheme 2). Therefore, our data indicate that the -
hydroxybutenolide is the only structural element required for
PLA2 covalent inhibition, which rules out a prominent role for the
pyrane ring previously thought[16] to be the other key element
actively involved in the irreversible modification of the enzyme.
Location of binding site(s)
Identification of the inhibitor binding site(s) on PLA2 was
performed through the following protocol: Unreacted, mono-
modified, and dimodified PLA2 forms previously isolated by RP
HPLC on a Vydak C4 analytical column were subjected to
disulfide bridge reduction with guanidinium chloride (GndCl)
and dithiothreitol (DTT) (50:1 molar excess with respect to the
protein), SH group alkylation (iodoacetamide in 10:1 molar
excess to the protein), and then enzymatic hydrolysis. The
endoprotease LysC, which cleaves peptide bonds adjacent to
lysine residues, was used as a proteolytic agent to locate the
putative reactive lysine residues. The peptide mixture so
obtained was then analyzed by LC ±MS. Hydrolysis of the intact
protein (Figure 2A) allowed us to obtain a full LysC peptide map
of the PLA2 amino acid sequence that was used as a reference for
the experiments on the modified PLA2 species. Excellent agree-
ment was observed between the measured and expected mass
values for all the peptides (Table 2). When the same procedure
was performed on the monomodified protein (Figure 2B), two
differences were observed in the HPLC chromatogram. The
N-terminal glycopeptide (residues 1 ± 14) disappeared (peak 8,
Figure 2) and a new peak characterized by a higher retention
time simultaneously appeared (peak 11, Figure 2). It is important
to point out that the residue 1 ±14 peptide fragment contains
the PLA2 glycosilation site at the Asn-13 residue and bears two
different glycoforms. The ESMS spectrum of this fraction, which
displays molecular masses of 2953.30.7 and 3115.70.2 Da, is
consistent with that expected for peptide 1 ±14 covalently
linked to the PM molecule (all masses are 444 Da higher than
those of the same peptide observed in the unreacted glyco-
protein). The presence of the modified 1 ±14 glycopeptide and
the absence of any other modified peptide indicate that the
monomodified PLA2 adduct consists of a homogeneous species
Table 1. Mass spectrometry analysis of PM/PLA2 reaction products.[a]
Frac-
tion
Measured
mass [Da]
Description of the species Expected
molecular
mass [Da]
1 16166.3 1.3 PLA2 (2 Met ox) Hex NAc2 Hex2 16166.4
16328.4 1.4 PLA2 (2 Met ox) Hex NAc2 Hex3 16328.6
16490.8 0.9 PLA2 (2 Met ox) Hex NAc2 Hex4 16490.8
2 16150.1 1.6 PLA2 (1 Met ox) Hex NAc2 Hex2 16150.3
16311.91.1 PLA2 (1 Met ox) Hex NAc2 Hex3 16312.5
16475.0 1.5 PLA2 (1 Met ox) Hex NAc2 Hex4 16474.7
3 16594.7 1.6 PLA2 (1 Met ox) Hex NAc2 Hex2PM 16594.8
16755.8 1.3 PLA2 (1 Met ox) Hex NAc2 Hex3PM 16757.0
16918.9 0.9 PLA2 (1 Met ox) Hex NAc2 Hex4PM 16919.2
4 17039.1 1.5 PLA2 (1 Met ox) Hex NAc2 Hex2 2PM 17039.3
17202.3 1.1 PLA2 (1 Met ox) Hex NAc2 Hex3 2PM 17201.5
17362.5 1.3 PLA2 (1 Met ox) Hex NAc2 Hex4 2PM 17363.7
[a] Fraction numbers are indicated in Figure 1.
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Figure 2. LC ±MS analysis of unmodified (A), monomodified (B) and dimodified
(C) PLA2 enzymes after reaction with PM and digestion by endoprotease LysC.
TIC relative total ion current. Mass spectrometry results are summarized in
Table 2.
that contains a single molecule of PM covalently bound to the
PLA2 N terminus (that is, the NH2 group of the Ile-1 residue; see
Scheme 1). In principle, the -amino group at the Lys-14 residue
is another potential binding site present in the 1 ±14 fragment.
However, this possibility was ruled out since no differences were
detected in the efficiency of LysC hydrolysis at the Lys-14/Ser-15
peptide linkage in the unmodified and modified PLA2, a finding
in conflict with the presence of such a sterically demanding
molecule at this Lys residue. The identification of the PLA2 N
terminus as virtually the only covalent PM binding site led us to
Table 2. Mass spectrometry analysis of the peptide mixture that results from
LysC hydrolysis of unmodifed, monomodified, and dimodified PLA2 (after
reaction with PM or MLD).[a]
Fraction Measured
mass [Da]
Description of the peptide Expected
molecular
mass [Da]
1 2187.2 0.2 48 ± 66 2187.1
2 2581.6 0.3 26 ± 47 (1 Met ox) 2581.7
3 2565.7 0.1 26 ± 47 2565.7
4 3165.6 0.6 95 ± 120 3166.0
5 1190.80.2 15 ± 25 1191.3
6 3014.3 0.8 48 ± 72 3015.6
7 1143.90.5 86 ± 94 1144.1
8 2507.8 0.8 1 ±14 Hex NAc2 Hex2 2508.1
2670.2 0.7 1 ±14 Hex NAc2 Hex3 2670.3
9 1417.2 0.6 125 ± 134 1416.8
10 1387.7 0.4 73 ± 85 1388.1
11 2953.3 0.7 1 ±14 Hex NAc2 Hex2PM 2952.6
3115.70.2 1 ±14 Hex NAc2 Hex3PM 3114.8
11b 2909.0 0.5 1 ±14 Hex NAc2 Hex2MLD 2908.6
3071.6 0.8 1 ±14 Hex NAc2 Hex3MLD 3070.8
12 2958.7 0.2 73 ± 94 2 PM 2958.8
12b 2915.2 0.6 73 ± 94 2 MLD 2914.4
[a] Fraction numbering is consistent with Figure 2 and Figure 4. The
numbers used for the peptide descriptions correspond to the residue
numbers in Scheme 1.
Scheme 2. The two mechanisms postulated for the PM±PLA2 inactivation reaction and the expected mass increments. The experimentally observed mass increment
was 444 Da (after NaBH4 reduction), which supports Mechanism 1.
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speculate on the possible origin of such a high binding
specificity. A noncovalent PM±PLA2 recognition process is very
likely to take place prior the covalent inactivation process. As
can be appreciated from visual inspection of the crystallo-
graphic coordinates of bee venom PLA2, a peculiar feature of
its tertiary structure is the folding of the N terminus back onto
the pocket that leads to the catalytic site. This unusual
structural arrangement is clearly relevant for the inhibition of
PLA2 catalytic activity (see below).
The two sites of covalent modification in the 2:1 PM±PLA2
adduct were identified by means of a protocol very similar to
that described above (Figure 2C). The results are consistent
with one binding site within the 1 ±14 peptide fragment(as in
the case of 1:1 adduct) and a second one located at the Lys-85
residue. Indeed, the fractions corresponding to the PLA2
fragments that consist of residues 73 ±85 and 86±94 (peaks
7 and 10, respectively, Figure 2C) disappeared from the
chromatogram and a new peak was observed (fraction 13)
whose ESMS analysis was in agreement with that expected for
the peptide fragment that contains residues 73 ±94 bound to
one PM molecule. It should be emphasized that the presence of
the inhibitor molecule at the Lys-85 residue prevented catalysis
of the hydrolysis of the peptide bond between residues 85 and
86 by LysC. Thus, the 2:1 inhibitor ± enzyme adduct also
appeared to be a homogeneous species that contains one
molecule of PM bound to the N terminus (the amino group of
the Ile-1 residue) and a second molecule of PM linked to the -
amino group of the Lys-85 residue.
PLA2 inhibition by MLD
The above-described experimental procedure was applied to the
case of MLD±PLA2 inhibition to attempt to put our results in a
broader perspective and to test the scope and the frame of
validity of our model. Remarkably, the results obtained in this last
set of experiments were in all respects equivalent to those
previously described for the PM molecule. The MLD±PLA2
reaction also proceeds a in few minutes and leads to a major
monomodified and a minor dimodified protein species product
(Figure 3 and Table 3). Again the measured PLA2 mass incre-
ments Mboundfree were of pivotal importance in the determi-
nation of the chemical mechanism involved in the enzyme
Figure 3. RP HPLC chromatogram of the separation of MLD/PLA2 reaction
products. Mass spectrometry analyses of the fractions are reported in Table 3.
inactivation process (Table 2). Even the results of the experi-
ments for the location of the MLD binding site(s) nicely matched
those of the related PM molecule and support covalent
modifications at the N terminus for the 1:1 adduct and at both
the N terminus and the Lys-85 residue for the 2:1 adduct
(Figure 4). It is noteworthy that the MLD molecule displays two
reactive electrophilic centers, namely the C-24 (in the pyran ring)
and C-25 (in the -hydroxybutenolide ring) free hemiacetal
groups. Nevertheless, we again detected no bidentate mode of
binding of MLD to PLA2 (that is, two nucleophilic attacks at the
Figure 4. LC ±MS analysis of unmodified (A), monomodified (B) and dimodified
(C) PLA2 enzymes after reaction with MLD and digestion by endoprotease LysC.
Mass spectrometry results are summarized in Table 2.
Table 3. Mass spectrometry analysis of MLD/PLA2 reaction products.[a]
Frac-
tion
Mesured
mass [Da]
Description of the species Expected
molecular
mass [Da]
1 16166.8 1.1 PLA2 (2 Met ox) Hex NAc2 Hex2 16166.4
16328.5 1.0 PLA2 (2 Met ox) Hex NAc2 Hex3 16328.6
16490.7 1.3 PLA2 (2 Met ox) Hex NAc2 Hex4 16490.8
2 16150.3 1.6 PLA2 (1 Met ox) Hex NAc2 Hex2 16150.3
16312.9 0.9 PLA2 (1 Met ox) Hex NAc2 Hex3 16312.5
16474.3 1.8 PLA2 (1 Met ox) Hex NAc2 Hex4 16474.7
3 16551.0 1.6 PLA2 (1 Met ox) Hex NAc2 Hex2 MLD 16550.8
16713.0 1.2 PLA2 (1 Met ox) Hex NAc2 Hex3 MLD 16713.0
16874.9 1.0 PLA2 (1 Met ox) Hex NAc2 Hex4 MLD 16875.2
4 16950.5 1.8 PLA2 (1 Met ox) Hex NAc2 Hex2 2 MLD 16951.3
17112.61.7 PLA2 (1 Met ox) Hex NAc2 Hex3 2 MLD 17113.5
17274.8 1.0 PLA2 (1 Met ox) Hex NAc2 Hex4 2 MLD 17275.7
[a] Fraction numbers are indicated in Figure 1.
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C-24 and C-25 atoms) since all MS data are fully consistent with
the exclusive involvement of the C-25 hemiacetal funtion in the
butenolide moiety of MLD. Before direct evidence for the exact
nature of chemical modification that occurs in MLD upon
binding to PLA2 was available, the possibility that two Lys
residues spatially or sequentially close to each other would
deliver a nucleophilic attack to both MLD reaction centers was
long considered a valid hypothesis,[16] particularly since PLA2
contains a segment with the sequence Lys94-Cys95-Tyr96-Lys97. On
the other hand, since this bidentate binding appears not to
occur, the pyran ring could well be involved in the inhibitor ±
enzyme recognition process at a different level, for instance it
may participate in the formation of favorable noncovalent
interactions (see below).
Molecular modeling studies
The final step in this study concerned the construction of a 3D
model of the PM±PLA2 complex. We aimed to achieve a better
understanding of the enzyme inactivation process at a molecular
level to shed more light on the origin of the remarkable specifity
(in terms of a noncovalent binding site) observed for these
molecules. All the molecular modeling work was performed on
the crystallographic structure of bee venom PLA2 with a
phospholipid transition state analogue in its active site (Protein
Databank (PDB) code 1POC).[18] The phospholipid analogue was
then taken away from the active site and replaced with the PM
molecule. The docking procedure was performed by using the
AFFINITY module of the INSIGHT II (version 1998) suite of
software (Accelrys Inc. , San Diego). This software module allows
a conformational grid search to maximize the favorable inter-
actions (Van der Waals, electrostatic, and hydrogen bonds)
between a drug and a receptor. This maximization is achieved by
optimization of both sets of 3D coordinates of the drug (its
conformation and positioning) and those of the protein active
site, which is usually defined by a distance criterion. The
experimental information on the location of the inhibitor
covalent binding site was used to correctly orientate the PM
molecule within the enzyme pocket. Accordingly, the polar tail of
the inhibitor, which contains the reactive center (-hydroxybu-
tenolide, ring E, Figure 5), faced the outer, solvent exposed
surface of the protein towards the N-terminal residue, while the
lipophilic tetracyclic system was located in the inner portion of
the pocket. Once the PM molecule was placed in proximity to
the catalytic site, AFFINITY calculations were performed. Adjust-
ments of both the PM molecule and the PLA2 active site were
allowed and the active site was defined as a 7 ä sphere around
the centroid of the PM molecule. The PM±PLA2 complex was
further optimized by standard molecular mechanics calculations
by using the AMBER force field. The final model obtained after all
these refinements is reported in Figure 5. Among the most
convincing features of this model, we noticed the excellent
shape complementarity of the hydrophobic core of the inhibitor
(rings A, B, C, and D) and the protein surface delimiting the active
site. It should be noted that in this orientation the PM C-25
hemiacetal carbon atom and the PLA2 N terminus are found in
close proximity, even though this distance was not forced by any
Figure 5. A) 3D model of the PM±PLA2 adduct. The protein backbone is
represented by a blue ribbon. Amino acid side chains are omitted for clarity,
except for those of Lys residues and the N-terminal group. The PM molecule is
displayed as a stick representation surrounded by a transparent solvent-
accessible surface. B) Expanded view of the model to show the details of the
interaction of PM with the PLA2 active site. Color code: carbon, gold; oxygen, red;
nitrogen, blue; hydrogen, white. Only heavy atoms are displayed, except for the
S55 hydroxy group and the N-terminal groups.
sort of constraint during the calculations. Ring A atoms (C1 ±C4
and CH3-20 and CH3-21) lie in the vicinity of (about 3.0 ä away
from) the Tyr-87 and His-34 residues, two of the three residues
that compose the PLA2 catalytic triad. The Asp-64 residue (the
third residue actively involved in PLA2 catalysis) is located further
away from the inhibitor at a distance of about 5.0 ä. The inhibitor
tetracyclic system appears to be literally sandwiched by several
amino acid side chains. The His-56 and His-11 residues stack with
the bottom () faces of ring A and ring B, respectively, whereas at
the top () face of the inhibitor the Met-86 side chain protrudes
towards the Me-18 residue (rings C and D). Towards the outer
side of the inhibitor, Tyr-87 and Ile-91 side chains make contacts
with rings B and C, respectively. The Ser-55 hydroxy group is
engaged in a hydrogen bond with the PM acetyl carbonyl group
attached to the C-24 hemiacetal group in pyran ring D.
The model proved particularly useful in attempts to unravel
the details of the mechanism of PLA2 inactivation at the atomic
level and strongly supports the view in which the initial event is a
noncovalent recognition between PM and the enzyme, followed
by nucleophilic attack by the PLA2 N terminus at the C-25
L. Gomez-Paloma et al.
670 ChemBioChem 2002, 3, 664 ±671
butenolide hemiacetal group. Indeed, the recognition could be
driven by a number of favorable interactions, such as Van der
Waals or hydrophobic interactions (water molecules are likely to
be released in the process) and probably H bond(s). These
interactions would in turn ensure the correct positioning of the
inhibitor within the binding pocket and thus bring the functional
groups involved in the formation of the Schiff base within
bonding distance of one another.
A structure-based rationalization of the formation of the
dimodified species appears to be more complicated. On the one
hand, the Lys-85 residue appears to be the second closest
nitrogen nucleophile to the inhibitor molecule when it is in the
binding pocket, whereas on the other hand the introduction of a
second PM molecule into the PLA2 active site appears to involve
a rather large conformational rearrangement. A possible spec-
ulation based on the present model is that there could be
additional room to accommodate a second inhibitor molecule in
another region of the same pocket. This hypothesis would imply
that the dimodified PLA2 species contains two inhibitor mole-
cules piled on top of each other and thus the large pocket
delimited by the three  helices of the enzyme is filled up
completely. However, since it is hard to make reasonable
predictions of the inhibitor ± PLA2 molar ratios under physiolog-
ical conditions, the biological relevance of the 2:1 adduct is not
clear at the present stage.
The overall picture reported in this paper may be instrumental
in the design of simplified PM analogues as novel lead
compounds for the treatment of acute and chronic inflammation.
Experimental Section
PLA2 ± inhibitor adduct analysis : Bee venom PLA2 (100 g, 6.2 nmol)
was incubated in Na2B4O7 solution (100 L; 10 mM, pH 7.4) in the
presence of a 5:1 molar excess of inhibitor (PM) at 40 for 5 min. The
resulting mixture was diluted with an equal volume of an NaBH4
(3 mM) and Na2B4O7 (10 mM) solution and incubated for 2 hours at 0C.
The reduction reaction was quenched by addition of HCl (5 L, 6M)
and the reaction products were fractionated by RP HPLC on a C4
column. Modified glycoproteins were analyzed by means of a linear
gradient from 25% to 95% of acetonitrile in 0.1% trifluoroacetic acid
(TFA) over 35 min. Elution was monitored at 220 nm. Individual
fractions were collected and identified by ESMS. Mass analysis was
performed on an API100 single quadrupole spectrometer (Applied
Biosystems) equipped with an electrospray ion source. Data were
acquired and elaborated by using the Biolmultiviewer program
(Applied Biosystems). Mass calibration was performed by means of
multiply charged ions from a separate injection of horse heart
myoglobin (Sigma; average molecular mass 16951.5 Da). All
masses are reported as average values.
Reaction with hydroxylamine : PLA2 was first treated with PM as
described above. After 5 minutes of incubation a hydroxylamine-
containing solution was added to obtain a final hydroxylamine
concentration of 0.6 mM (molar protein:hydroxylamine1:10) and
the mixture was left to react for 2 hours at 40 C. Reaction products
were analyzed by RP HPLC and ESMS under the same conditions as
previously described. The same procedure was also performed on
the glycoprotein ± inhibitor complex after a 2 hour reduction with
NaBH4.
Location of the binding site(s) : Unreacted, monomodified, and
dimodified PLA2 were purified by HPLC and individually underwent
disulfide bond reduction. Each species was dissolved in tris(hydroxy-
methyl)aminomethane (Tris ; 100 mM), ethylenediaminotetraacetate
(EDTA; 1 mM), GndCl (6M), and DTT (5 mM) at pH 7.5 and incubated
under a nitrogen atmosphere for 2 hours at 37 C. The free thiol
groups obtained were alkylated by addition of an equal volume of a
solution of Tris (100 mM), EDTA (1 mM), GndCl (6M), and iodacetam-
mide (50 mM) at pH 7.5. The alkylation reaction was allowed to
proceed for 30 minutes in the dark at room temperature and was
than quenched by HPLC injection.
Alkylated species were digested with the endoprotease LysC in
ammonium bicarbonate (50 mM, pH 8.5) at 37.0 C for 4 h at a 1:50
(w:w) LysC:protein ratio. Proteolytic fragments were analyzed by
LC±MS performed on an API100 single quadrupole electrospray
spectrometer (Applied Biosystems) equipped with two Perkin-Elmer
Series 200 LC isocratic pumps. Chromatographic separation was
carried out on a Phenomenex C18 column by means of a 40 min
linear gradient from 15 ±55% acetonitrile in 2% formic acid and
0.1% TFA. Mass spectra were acquired in an m/z interval of 600 ±
1800.
Molecular modeling : All molecular modeling was performed on a
Silicon Graphics Indigo 2 workstation equipped with a R10000
processor. For AFFINITY calculations (InsightII version 1998, Accelrys,
Inc. , San Diego, USA) the CVFF force field was used with standard
parameters. The 3D coordinates of PLA2 were obtained from the PDB
archive (http://www.rcsb.org/pdb/; PDB code for bee venom PLA2
crystallographic structure: 1POC). The input PM±PLA2 complex for
the AFFINITY calculations was obtained by visual docking the PM
molecule into the hydrophobic pocket of PLA2. Once the AFFINITY
docking procedure was completed, a full energy minimization was
carried out on the PM±PLA2 complex by using the conjugate
gradient algorithm until the maximum derivative was less then
0.1 Kcal.
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